Dry And Wet Age-Related Macular Degeneration – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
MARKET OUTLOOK
Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative, neovascular) form of the disease. Currently available therapies targeting vascular endothelial growth factor (VEGF) have been shown to maintain and even improve visual acuity in wet AMD patients, including Roche / Genentech’s Avastin (bevacizumab), Roche / Genentech’s Lucentis (ranibizumab), Regeneron’s Eylea (aflibercept), and Novartis’s Beovu (brolucizumab). Using national, longitudinal, patient-level U.S. claims data, this report examines recent trends in the management of wet AMD both for newly diagnosed patients and patients filling a prescription for a key therapy in the first six months of 2021.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed wet AMD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet AMD patients?
- How has Novartis’s Beovu been integrated into the treatment algorithm, and what is its source of business?
- What percentage of wet AMD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of wet AMD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Roche / Genentech, Regeneron, Novartis
Key drugs: Avastin, Lucentis, Eylea, Beovu
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Table of contents
- Dry And Wet Age-Related Macular Degeneration - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Wet AMD US March 2022
- Treatment Algorithms CDA Wet AMD US 2022 Dashboard
Amanda Le, M.S., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. Prior to joining the company, she worked on research projects focusing on the effects of aging on the development of oral premalignancies, head and neck cancers, and handedness in surgery. She holds a master’s degree in medical sciences from Boston University School of Medicine and a bachelor’s degree in biochemistry from Boston College.